Sandoz
Frank Striebel is a seasoned professional in clinical pharmacology, currently serving as Senior Global Clinical Pharmacology Manager at Sandoz since November 2020. Prior experience includes roles at MorphoSys AG, where Frank held positions as Associate Director Clinical Pharmacology & Bioanalytics, Senior Scientist, and Scientist, focusing on pivotal projects such as the development of tafasitamab, which led to successful regulatory submissions. Earlier research experience includes postdoctoral positions at the Max Planck Institute for Biochemistry and ETH Zurich. Frank Striebel holds a PhD from ETH Zurich and has degrees in biochemistry from the Technical University of Munich at both the master's and bachelor's levels.
This person is not in any teams
This person is not in any offices
Sandoz
30 followers
As a division of the Novartis Group, their purpose is to discover new ways to improve and extend people's lives. They contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine.